Table 5.6d

Immunosuppression Use: Antirejection Treatment from Transplant

to One Year Posttransplant, 1993 to 2002

Recipients with Kidney Transplants

		Year of Transplant
		1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
Transplants		10,360	10,646	11,073	11,389	11,696	12,432	12,737	13,573	14,239	14,774
Tx with Antirejection Treatments		3,954	3,361	4,318	5,835	3,445	2,654	2,442	2,381	2,396	2,185
Antibodies	Category Usage	57.2%	53.4%	32.1%	16.7%	27.1%	36.9%	37.1%	35.6%	37.5%	38.6%
	ALG	20.6%	18.7%	5.8%	0.3%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	ATG/NRATG/NRATS	0.4%	0.8%	2.2%	3.4%	6.5%	8.1%	5.9%	2.9%	2.5%	2.3%
	OKT3	43.9%	43.0%	26.5%	13.8%	21.6%	26.3%	18.8%	14.6%	11.7%	10.8%
	Thymoglobulin	0.0%	0.0%	0.0%	0.1%	0.2%	0.9%	7.9%	12.9%	18.0%	23.6%
	Zenapax	0.0%	0.0%	0.0%	0.0%	0.2%	3.4%	5.8%	3.4%	2.9%	1.9%
	Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.3%	1.6%	4.0%	5.0%	3.4%
	Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%
Corticosteroids	Category Usage	81.0%	78.7%	58.0%	38.5%	58.6%	78.7%	78.4%	80.1%	80.2%	79.6%
	Steroids	81.0%	78.7%	58.0%	38.5%	58.6%	78.7%	78.4%	80.1%	80.2%	79.6%
Antimetabolites	Category Usage	0.1%	0.2%	0.2%	0.3%	0.5%	0.1%	0.1%	0.3%	0.2%	0.1%
	Cytoxan	0.1%	0.2%	0.1%	0.2%	0.3%	0.1%	0.1%	0.3%	0.1%	0.1%
	Methotrexate	0.0%	0.0%	0.1%	0.1%	0.2%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 3, 2004.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.